Drugmakers seeking to register a biosimilar product in Singapore should provide complete information on the development, control and manufacture of the drug and its active ingredient, a new guidance says. Comparability studies between the biosimilar product and its reference product also must be submitted, the Health Sciences Authority says in the guidance posted on its website on 1 August 2009.
Singapore outlines process to register biosimilars
Home/Guidelines
|
Posted 16/10/2009
0
Post your comment
The guidance document describes the basic principles of a similar biological product, as well as the procedures and requirements for registration of a similar biological product.
The document is intended to:
- introduce the concept of similar biological products
- outline the basic principles to be applied for similar biological products
- describe the procedure and documentary requirements for submitting an application for a similar biological product
- describe the pharmacovigilance requirements for similar biological products
- describe the post-approval batch release requirements for similar biological products
The guidance document is adapted mainly from the EMEA guidelines on similar biological products, with consideration of Singapore’s local regulatory environment.
References:
FDAnews Drug Daily Bulletin Vol. 6 No. 188, 28 September 2009. Singapore outlines process to register biosimilars.
Guidance on registration of similar biological products in Singapore, August 2009.
Source: FDAnews Drug Daily Bulletin
Policies & Legislation
WHO to remove animal tests and establish 17 reference standards for biologicals
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
US guidance to remove biosimilar comparative efficacy studies
New guidance for biologicals in Pakistan and Hong Kong’s independent drug regulatory authority
Canada poised to remove requirement for Phase III trials for biosimilars
European position paper on AI in medicinal product lifecycle
Related content
New guidance for biologicals in Pakistan and Hong Kong’s independent drug regulatory authority
Home/Guidelines Posted 20/10/2025
Canada poised to remove requirement for Phase III trials for biosimilars
Home/Guidelines Posted 22/07/2025
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment